Community post

Adaptive Phage Therapeutics (APT) has received Orphan drug designation from the FDA for the use of its PhageBank™ (a continually expanding library of phages) to treat prosthetic joint infections. APT will now be eligible for seven years of U.S. market exclusivity upon FDA approval, will pay less in marketing application fees, will be exempt from performing clinical studies in pediatric patients, and will receive tax credits that reduce clinical development costs.